') no-repeat 50% 50%;mask:url('data:image/svg+xml, ') no-repeat 50% 50%;-webkit-mask-size:cover;mask-size:cover;margin-left:.625rem;transform:rotate(0);transition:transform .1s}.dropdown-toggle:not([class*=btn-]):focus,.dropdown-toggle:not([class*=btn-]):hover{color:#2196f3;font-weight:500;background-color:inherit}.form-control{height:calc(1.6568em + 1.25rem + 2px);background-clip:border-box;-webkit-appearance:none;filter:none}.form-control:-webkit-autofill,.form-control:-webkit-autofill:active,.form-control:-webkit-autofill:focus,.form-control:-webkit-autofill:hover{box-shadow:0 0 0 30px #fff inset!important}.form-control:disabled{color:#999;background-color:#f5f5f5}.form-control,.form-control:focus,.form-control:focus-visible{box-shadow:none}.input-group-sm .form-control{height:2.10419375rem}.form-check-new{position:relative;display:flex}.form-check-new+.form-check-new{margin-top:.625rem}.form-check-new:not(.inline){margin-bottom:.25rem}.form-check-new:not(.inline)>xetf-checkbox{margin-right:.875rem}.text-check{line-height:1.5;font-size:.75rem;color:#444;padding-top:1px}.text-check.sm{font-size:.625rem;padding-top:2px}.text-check a{font-weight:600}.check-container{display:flex;align-items:center;margin-bottom:0;cursor:pointer}.check-container:not(.disabled):hover{color:#666}.check-container .checkbox,.check-container .checkbox input,.check-container .checkbox span{width:var(--checkbox-size);height:var(--checkbox-size)}.check-container .checkbox input{border:0;background:0 0;display:inline-block;margin:0;cursor:pointer;position:absolute;visibility:visible;opacity:0;z-index:2}.check-container .checkbox input:checked~span:after{opacity:1}.check-container .checkbox input:focus~span,.check-container .checkbox input:hover~span{box-shadow:0 4px 4px #0000001f}.check-container .checkbox span{display:inline-block;position:relative;text-align:center;border-style:solid;border-color:#999;color:#42a5f5;transition:box-shadow .15s ease-in}.check-container .checkbox span:after{content:"";position:absolute;opacity:0;transition:opacity .15s ease-in}.check-container .checkbox span:checked:after{opacity:1}.fs-sm{font-size:.8125rem!important}.fs-xs{font-size:.75rem!important}.fs-larger{font-size:larger}.cursor-pointer{cursor:pointer}.w-100{width:100%!important}.hidden{visibility:hidden}.nowrap{white-space:nowrap}.input-group{margin-bottom:1.25rem}.input-group .form-control::placeholder{color:#aaa;font-weight:500}.input-group .form-control::-webkit-search-cancel-button{display:none}.input-group .form-control::-webkit-inner-spin-button,.input-group .form-control::-webkit-outer-spin-button{-webkit-appearance:none;margin:0}.input-group:focus-within .input-group-text{border-color:#999}.input-group-text{font-weight:500;transition:border-color .15s ease-in-out,box-shadow .15s ease-in-out}.input-group-text xetf-icon{color:#bbb;font-size:.9375rem;z-index:4}.input-group-text:first-child{border-right:0;border-top-right-radius:0;border-bottom-right-radius:0}.input-group-text+.form-control{border-left:0}.input-group-text+.form-control{padding-left:0}.input-group-text+.form-control:disabled{border-left-width:0;padding-left:2.625rem!important;margin-left:-2.625rem!important}html{display:flex;flex-direction:column;scroll-behavior:smooth}body{min-height:100vh;display:flex;flex-direction:column;flex:1}.content{padding:1.25rem .625rem;flex-grow:1;z-index:1}app-root{transition:.15s ease-in}.nav-link{position:relative;transition:.15s ease-in-out}.nav-pills{--bs-nav-pills-border-radius:5px;--bs-nav-pills-link-active-color:#fff;--bs-nav-pills-link-active-bg:#2196f3;margin-bottom:1.25rem}.nav-pills .nav-link{color:#777}.nav-pills .nav-link:not(.active):focus,.nav-pills .nav-link:not(.active):hover{color:#324148}.toolbar-main-items{overflow-x:auto;overflow-y:hidden}.toolbar-main-items:after,.toolbar-main-items:before{content:"";position:absolute;top:0;width:30px;height:40px;z-index:1;transition:box-shadow .3s;pointer-events:none}.toolbar-main-items:before{left:0}.toolbar-main-items:after{right:0}.toolbar-main-items::-webkit-scrollbar{display:none}.toolbar-container{display:flex;flex-wrap:wrap;position:relative}.toolbar-container .toolbar-main-items,.toolbar-container .toolbar-misc-items{height:40px}.toolbar-container .toolbar-main-items{position:static;flex:1 0 100%}.toolbar-container .toolbar-misc-items{position:relative;display:flex;flex-wrap:nowrap;flex-grow:1}.toolbar-container .border-placeholder{position:absolute;left:0;right:0;top:38px;height:2px;background-color:#e5e5e5}.toolbar-container .nav-pills{justify-content:space-between;flex-wrap:nowrap;margin-bottom:0}.toolbar-container .nav-pills>:not(.separator){text-align:center;flex:1}.toolbar-container .separator{position:relative}.toolbar-container .separator:after{content:"";position:absolute;height:14px;width:1px;right:1px;border-right:1px solid #c9c9c9;top:calc(50% - 7px)}.toolbar-container .nav-link{position:relative;white-space:nowrap;-webkit-user-select:none;user-select:none;line-height:20px;padding:10px 20px;color:#333;border-radius:0}.toolbar-container .nav-link:focus,.toolbar-container .nav-link:hover{color:#2196f3!important}.toolbar-container .nav-link.active{color:#2196f3!important;background-color:transparent!important}.toolbar-container .nav-link.active:after{content:"";position:absolute;bottom:0;left:0;right:0;height:4px;background-color:#2196f3;z-index:2}.new-navbar-collapse{position:absolute;inset:2.25rem 0 auto!important;z-index:600;padding:1.25rem 0;background-color:#324148;transform:translateY(-520px);will-change:transform;transition:transform .3s ease-in}.new-navbar-collapse .dropdown-menu{overflow:hidden;border-top-left-radius:.3125rem;border-top-right-radius:.3125rem}.navbar{font-size:.75rem;font-weight:600}.navbar .dropdown-item,.navbar .dropdown-menu,.navbar .dropdown-toggle,.navbar .navbar-nav-link{font-size:.75rem;white-space:nowrap}.navbar .dropdown-toggle:hover{font-weight:600}.navbar .nav-item>a{position:relative}.navbar-brand img{height:1.625rem;display:block}.navbar-nav{justify-content:space-evenly}.navbar-nav-link{position:relative;display:flex;cursor:pointer;padding:1rem 1.75rem;outline:0;transition:.15s ease-in-out}.navbar-toggler{z-index:601;border:0;cursor:pointer;padding:.75rem 5px;transition:.15s ease-in-out}.navbar-toggler:last-child{margin-left:5px;margin-right:-10px}@media (max-width:1199.98px){.navbar-brand img{height:1.25rem}.navbar-expand-xl .navbar-nav-link.dropdown-toggle:after{position:absolute;right:calc(1.5rem + 7px);margin:0}.navbar-expand-xl .navbar-nav>.nav-item>.dropdown-menu{width:100%;border-radius:0}}.navbar-dark{--bs-navbar-color:#fff;--bs-navbar-hover-color:#fff;--bs-navbar-disabled-color:rgba(255, 255, 255, .5);--bs-navbar-active-color:#fff;--bs-navbar-brand-color:#fff;--bs-navbar-brand-hover-color:#fff;--bs-navbar-toggler-border-color:rgba(255, 255, 255, .1);--bs-navbar-toggler-icon-bg:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 30 30'%3e%3cpath stroke='%23fff' stroke-linecap='round' stroke-miterlimit='10' stroke-width='2' d='M4 7h22M4 15h22M4 23h22'/%3e%3c/svg%3e");color:#fff;background-color:#324148}.navbar-dark .navbar-nav-link{color:#fff;padding:1rem}.navbar-dark .navbar-nav-link:focus,.navbar-dark .navbar-nav-link:hover{color:#fff;background-color:#00000026}.table{margin-bottom:0;color:#324148}.table td,.table th{vertical-align:middle;padding-left:2px;padding-right:2px}.table th{font-weight:500}.table thead th{vertical-align:middle;border-bottom:2px solid #e5e5e5}.table>:not(:first-child){border-top:0}.table tbody tr:last-child>*{border-bottom-width:0}.table.last-column-end td:last-child,.table.last-column-end th:last-child{text-align:right}h1,h2,h3{letter-spacing:-.015em;font-weight:700}.text-default{color:#324148!important}a.text-default:not(.btn):not(.td_btn):not(.vc_btn){transition:color .15s ease-in-out}a.text-default:focus,a.text-default:hover{color:#324148bf}.profile-card h1{font-size:1.875rem;font-weight:700;margin-bottom:0;line-height:1}@media (max-width:767.98px){.profile-card{margin-bottom:1rem}.profile-card h1{font-size:1.25rem}.profile-card .top-info.desktop-only{display:none}}.profile-card .card-body{padding-bottom:0}.profile-card .profile-main-info{display:flex;flex-wrap:wrap;align-items:center;font-size:.625rem}.profile-card .profile-main-info.with-bottom-space>*{margin-bottom:1.125rem}.profile-card .profile-main-info .badge.badge-light{padding-top:7px;padding-bottom:7px}.profile-card .separated-properties>button:not(:first-child):not(:empty):not(.badge):before,.profile-card .separated-properties>span:not(:first-child):not(:empty):not(.badge):before{content:"|";color:#c9c9c9;margin-left:.25rem;margin-right:.25rem}.profile-card .separated-properties>span.badge:not(:last-child){margin-right:.625rem!important}.profile-card .nav-pills{margin-bottom:1.125rem}.profile-card .top-info{display:flex;flex-wrap:wrap;min-width:150px}.profile-card .top-info .top-info-column{position:relative;margin-bottom:1.125rem}.profile-card .top-info .top-info-column>.text-muted{display:flex;align-items:center;white-space:nowrap}.profile-card .top-info .top-info-column:not(:last-child){padding-right:1.25rem;margin-right:1.25rem}.profile-card .top-info .top-info-column:not(:last-child):after{content:"";position:absolute;height:14px;width:1px;right:1px;border-right:1px solid #c9c9c9;top:calc(50% - 7px);padding:0 1.25rem}.profile-card .top-info .value{font-size:.875rem;line-height:130%;font-weight:700}.profile-card .top-info .text-muted{font-size:.625rem}.profile-card .top-info .text-muted>xetf-icon{margin-left:.3125rem;color:#1976d2}.profile-card .provider-icon-wrapper{display:flex;align-items:flex-start;margin-bottom:.625rem}.profile-card .provider-icon-wrapper .provider-logo{display:block}.profile-card .provider-icon-wrapper .provider-logo{height:50px;min-width:50px;overflow:hidden;margin:0 1.25rem auto 0}.profile-card .provider-icon-wrapper .investment-name-wrapper{display:flex;flex-direction:column}.profile-card .provider-icon-wrapper .investment-name-wrapper .investment-name{display:flex;flex-direction:row}.profile-card .provider-icon-wrapper .investment-name-wrapper xetf-icon{color:#1976d2}.profile-card .toolbar-container{border-top:2px solid #e5e5e5}.profile-card .toolbar-container .toolbar-main-items{border-bottom-left-radius:5px}.profile-card .toolbar-container.with-misc-items .toolbar-main-items .nav-item .nav-link{padding-left:14px;padding-right:14px}@media (max-width:767.98px){.profile-card .toolbar-container.with-misc-items .toolbar-main-items .nav-item .nav-link{min-width:calc((100vw - 1.25rem)/ 3)}}.profile-card .toolbar-container.with-misc-items .toolbar-misc-items{justify-content:space-evenly}.profile-card .toolbar-container.with-misc-items .toolbar-misc-items>:not(.separator){padding-left:1.75rem;padding-right:1.75rem}.profile-card .toolbar-container.with-misc-items .toolbar-misc-items xetf-icon{display:block}.profile-card .border-placeholder{display:none}a>xetf-icon{margin-bottom:2px}.app-container{width:100%;margin:0 auto}a{cursor:pointer}.auth-offer-container{position:relative;display:block;min-height:150px}.btn-product-stock{background:0 0;color:inherit;border:none;padding:0;font:inherit;cursor:pointer;outline:inherit;white-space:nowrap;line-height:2}.btn-product-stock xetf-icon{color:inherit!important;margin-bottom:2px}.course-value{font-size:1.625rem;font-weight:700;margin-bottom:0;margin-right:1.5rem}.course-percentage{font-size:1rem;font-weight:700}.card-columns-ordered>*{page-break-inside:avoid!important;break-inside:avoid!important}
Achilles Therapeutics PLC Achilles Therapeutics PLC A
Achilles Therapeutics PLC Aktie ISIN: US00449L1026 WKN: A3CUPM Ticker: 698 Biotechnologie Biotechnologie
39,43 Mio. € Marktkapitalisierung Kurs, Beschreibung, Chart, Renditen, Kennzahlen Achilles Therapeutics PLC Aktienkurs
Die Achilles Therapeutics PLC Aktie ist bei insgesamt 1 Online Broker(n) sparplanfähig. Bei 1 Anbieter(n) davon ist die Achilles Therapeutics PLC Aktie aktuell kostenfrei im Sparplan erhältlich. Die Mindestsparrate beträgt 10 €.
Wichtige Kennzahlen und Stammdaten zur Achilles Therapeutics PLC Aktie.
39,43 Mio. € KGV 0,52 KBV 0,22 KUV — KCV -0,65 Ausgegebene Aktien 41 Mio. Stück
Achilles Therapeutics PLC ist ein biopharmazeutisches Unternehmen. Es entwickelt neuartige Krebsimmuntherapien, die auf klonale Neoantigene abzielen. Das Unternehmen hat zwei laufende Studien, die CHIRON-Studie bei Patienten mit nicht-kleinzelligem Lungenkrebs und die THETIS-Studie bei Patienten mit rezidivierendem oder metastasiertem Melanom.
Achilles Therapeutics PLC ist in folgendem Land registriert: Vereinigte Staaten (USA) (Börse: USNASD).
Hier siehst du die Wertentwicklung der Achilles Therapeutics PLC Aktie.
Zeitraum Performance 1 Woche -2,65 % 1 Monat +26,03 % 3 Monate -7,54 % 6 Monate -47,43 % 1 Jahr -60,00 % Lfd. Jahr +15,00 %
Mit einer (erwarteten) Jahresdividende von — ergibt sich zum aktuellen Kurs der Aktie eine Dividendenrendite von —.
Dividendenart — (Erwartete) Jahresdividende — Dividendenrendite —
Stammdaten werden bereitgestellt von Morningstar (Aktien, ETFs, Fonds), CoinGecko (Kryptowährungen) und der Isarvest GmbH. Kursdaten sind mindestens 15 Minuten zeitverzögerte Börsenkurse (Aktien, ETFs, Fonds) oder NAV-Kurse (ETFs, Fonds). Realtime-Kurse – sofern verfügbar – stammen von den Anbietern und der Lang & Schwarz (Aktien, ETFs, Fonds) und CoinGecko (Kryptowährungen).
Die Isarvest GmbH übernimmt für die dargestellten Informationen keine Gewährleistung und kann nicht sicherstellen, dass die Daten vollständig und genau sind.
Affiliate Hinweis * Bei den mit Sternchen (*) gekennzeichneten Links handelt es sich um Werbe- oder Affiliate-Links. Wenn du über diesen Link etwas kaufst oder abschließt, erhalten wir eine Vergütung des Anbieters. Dir entstehen dadurch keine Nachteile oder Mehrkosten. Wir verwenden diese Einnahmen, um unser kostenfreies Angebot zu finanzieren. Vielen Dank für deine Unterstützung.
Bitte Javascript aktivieren